Baseline demographics and clinical characteristics of patients with PV or ET receiving therapy with PEG-IFN-α-2a
| Characteristic . | PV (n = 43) number (range or %) . | ET (n = 39) number (range or %) . |
|---|---|---|
| Median age (range) | 54 (24-78) | 53 (19-75) |
| Months, diagnosis to study entry | 50 (0-350) | 34 (1-277) |
| Number JAK2V617F mutant (%) | 43 (100%) | 19 (48%) |
| Median % JAK2V617F allele burden | 65 | 23 |
| Abnormal karyotype | 3 (7%) | 3 (7.5%) |
| Number of prior therapies | 1 (0-4) | 2 (0-4) |
| Phlebotomy (%) | 32 (74%) | Not applicable |
| Hydroxyurea (%) | 20 (47%) | 28 (70%) |
| Anagrelide (%) | 9 (21%) | 22 (55%) |
| IFN-α (%) | 9 (21%) | 6 (15%) |
| Untreated (except phlebotomy in PV) | 22 (51%) | 9 (23%) |
| Characteristic . | PV (n = 43) number (range or %) . | ET (n = 39) number (range or %) . |
|---|---|---|
| Median age (range) | 54 (24-78) | 53 (19-75) |
| Months, diagnosis to study entry | 50 (0-350) | 34 (1-277) |
| Number JAK2V617F mutant (%) | 43 (100%) | 19 (48%) |
| Median % JAK2V617F allele burden | 65 | 23 |
| Abnormal karyotype | 3 (7%) | 3 (7.5%) |
| Number of prior therapies | 1 (0-4) | 2 (0-4) |
| Phlebotomy (%) | 32 (74%) | Not applicable |
| Hydroxyurea (%) | 20 (47%) | 28 (70%) |
| Anagrelide (%) | 9 (21%) | 22 (55%) |
| IFN-α (%) | 9 (21%) | 6 (15%) |
| Untreated (except phlebotomy in PV) | 22 (51%) | 9 (23%) |